ArticleAmerican journal of preventive medicine2025
Lung Cancer Screening Rates in the United States: Contribution of the 2020 NHIS Estimates to National and State-Level Trends.
Article in American journal of preventive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cost-Effectiveness of Smoking Cessation Interventions Integrated Into Lung Cancer Screening.JAMA network open · 2026Article
- Article
- Feasibility of Using College Students to Increase Cancer Screening Behaviors Among Their Parents.International journal of environmental research and public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionThe U.S. Preventive Services Task Force (USPSTF) has recommended annual lung cancer screening with low-dose computed tomography since 2013 for eligible populations who currently smoke or have formerly smoked. However, U.S. lung cancer screening rates from different studies have been inconsistent, and limited data are available for trend analysis.
methodsUsing lung cancer screening data from the 2020 National Health Interview Survey (NHIS) and the 2022-2023 Behavioral Risk Factor Surveillance System (BRFSS), the study team estimated recent lung cancer screening rates among eligible adults. They also analyzed data from previous years to examine trends from 2010 to 2023.
resultsBased on NHIS data, an estimated 8,247,101 (95% CI=7,634,267, 8,859,936) U.S. adults were eligible for lung cancer screening in 2020 per the 2013 USPSTF criteria. A similar number (8,039,236) were estimated in 2022 from BRFSS using the same eligibility criteria, with an additional 5,364,797 newly eligible individuals based on expanded 2021 USPSTF criteria. Lung cancer screening rates based on the 2013 criteria increased significantly from 3.8% in 2010 to 15.9% in 2020 (NHIS data), and to 21.8% in 2022 (BRFSS data). However, the 2022 screening rate among the newly eligible population (13.0%) was lower than that of individuals eligible under the 2013 criteria.
conclusionsThe 2020 NHIS estimates contributed to understanding trends in lung cancer screening rates while indicating that the Healthy People 2030 target of 7.5% of eligible screened would benefit from reassessment. Despite significant increases over the past decade, overall lung cancer screening rates remain low, and further research is needed to better understand the modest U.S. uptake of lung cancer screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.